A phase 2 trial of prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-refractory metastatic castration-resistant prostate cancer (mCRPC).

被引：9
|
作者：
Petrylak, Daniel Peter
Smith, David C.
Appleman, Leonard Joseph
Fleming, Mark T.
Hussain, Arif
Dreicer, Robert
Sartor, A. Oliver
Shore, Neal D.
Vogelzang, Nicholas J.
Youssoufian, Hagop
DiPippo, Vincent A.
Stambler, Nancy
Huang, Kathleen
Israel, Robert Joseph
机构：
[1] Yale Univ, Med Ctr, New Haven, CT USA
[2] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA
[3] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
[4] Virginia Oncol Associates, US Oncol Res, Hampton, VA USA
[5] Univ Maryland, Ctr Canc, Baltimore, MD 21201 USA
[6] Cleveland Clin, Cleveland, OH 44106 USA
[7] Tulane Univ, New Orleans, LA 70118 USA
[8] Atlantic Urol Clin, Carolina Urol Res Ctr, Myrtle Beach, SC USA
[9] Comprehens Canc Ctr Nevada, Las Vegas, NV USA
[10] Progen Pharmaceut Inc, Tarrytown, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.5023
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5023
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A phase II trial of prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-refractory metastatic castration-resistant prostate cancer (mCRPC).
    Petrylak, Daniel Peter
    Smith, David C.
    Appleman, Leonard Joseph
    Fleming, Mark T.
    Hussain, Arif
    Dreicer, Robert
    Sartor, A. Oliver
    Shore, Neal D.
    Vogelzang, Nicholas J.
    Youssoufian, Hagop
    Olson, William C.
    Stambler, Nancy
    Huang, Kathleen
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [2] Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): A phase I trial in metastatic castration-resistant prostate cancer (mCRPC) previously treated with a taxane
    Petrylak, Daniel Peter
    Kantoff, Philip W.
    Mega, Anthony E.
    Vogelzang, Nicholas J.
    Stephenson, Joe
    Fleming, Mark T.
    Stambler, Nancy
    Petrini, Michaela
    Huang, Kathleen
    Israel, Robert Joseph
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [3] Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): A phase I trial in metastatic castration-resistant prostate cancer (mCRPC) previously treated with a taxane
    Petrylak, Daniel Peter
    Kantoff, Philip W.
    Mega, Anthony E.
    Vogelzang, Nicholas J.
    Stephenson, Joe
    Fleming, Mark T.
    Stambler, Nancy
    Petrini, Michaela
    Blattman, Sara
    Israel, Robert Joseph
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [4] Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): A phase I trial in taxane-refractory prostate cancer
    Petrylak, D. P.
    Kantoff, P. W.
    Rotshteyn, Y.
    Israel, R. J.
    Olson, W. C.
    Ramakrishna, T.
    Morris, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [5] A PHASE 2 TRIAL OF PROSTATE SPECIFIC MEMBRANE ANTIGEN ANTIBODY DRUG CONJUGATE (PSMA ADC) IN TAXANE-TREATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
    Petrylak, Daniel
    Smith, David C.
    Appleman, Leonard J.
    Fleming, Mark
    Hussain, Arif
    Dreicer, Robert
    Sartor, A. Oliver
    Shore, Neil
    Vogelzang, Nicholas J.
    Youssoufian, Hagop
    Olson, William
    Stambler, Nancy
    Huang, Kathleen
    Israel, Robert
    JOURNAL OF UROLOGY, 2014, 191 (04): : E813 - E814
  • [6] Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): A phase I trial in metastatic castration-resistant prostate cancer (mCRPC) previously treated with a taxane.
    Mega, Anthony E.
    Petrylak, Daniel Peter
    Kantoff, Philip
    Stephenson, Joe
    Vogelzang, Nicholas J.
    Dreicer, Robert
    Shore, Neal D.
    Stambler, Nancy
    Carpenito, Jennifer
    D'Ambrosio, Paul
    Israel, Robert Joseph
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [7] Prostate Specific Membrane Antigen Antibody Drug Conjugate (PSMA ADC): a Phase 1 Trial in Castration-Resistant Metastatic Prostate Cancer (mCRPC)
    Petrylak, D.
    Kantoff, P.
    Mega, A.
    Stephenson, J.
    Vogelzang, N.
    Fleming, M.
    Blattman, S.
    Stambler, N.
    D'Ambrosio, P.
    Israel, R. J.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 75 - 75
  • [8] Prostate-specific membrane antigen antibody-drug conjugate (PSMA ADC): A phase I trial in taxane-refractory prostate cancer.
    Petrylak, D. P.
    Kantoff, P. W.
    Frank, R. C.
    Shore, N. D.
    Rotshteyn, Y.
    Israel, R. J.
    Olson, W. C.
    Ramakrishna, T.
    Morris, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [9] First-in-human phase I trial of prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-refractory prostate cancer
    Kantoff, P.
    Petrylak, D. P.
    Pomerantz, M.
    Israel, R. J.
    Olson, W. C.
    Ramakrishna, T.
    Morris, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [10] Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): A phase I trial in men with prostate cancer previously treated with taxane.
    Petrylak, Daniel Peter
    Kantoff, Philip W.
    Mega, Anthony E.
    Dreicer, Robert
    Frank, Richard C.
    Shore, Neal D.
    Morris, Stephen
    Olson, William C.
    Israel, Robert Joseph
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
12345